- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386980
Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed
November 2, 2021 updated by: Sorrento Therapeutics, Inc.
A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed
Efficacy and safety study of resiniferatoxin versus placebo to manage pain in patients with knee osteoarthritis whose TKR surgery is delayed
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
This study evaluates the efficacy and safety of intra-articular resiniferatoxin (RTX) versus placebo to manage pain in patients with osteoarthritis of the knee whose Total Knee Replacement surgery is delayed.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to give informed consent and comply with the study
- Diagnosis of osteoarthritis (OA) in the index knee
- Combined WOMAC A (pain) and C (function) subscale score of ≥ 23 at screening, using the WOMAC 5-point Likert scale
- Eligible for total knee replacement (TKR) surgery but unable to schedule surgery or undergo scheduled surgery
- In good general health; American Society of Anesthesiologists (ASA) physical status category ≤3
- Willing to use contraception for at least 30 days after receiving the study drug
- Able to understand and complete study-related forms and adequately communicate with the Investigator and site staff
Exclusion Criteria:
- Pre-existing osteonecrosis, subchondral insufficiency fracture, or knee pain attributable to disease other than OA which may confound the ability to assess response to treatment
- Concurrent medical or arthritic conditions that could interfere with evaluation of the index knee joint including, metabolic diseases, gout/pseudogout, hemochromatosis, acromegaly, fibromyalgia, rheumatoid arthritis, or other inflammatory arthropathies affecting the knee joint
- Participants with significant pain in the back or other joints (ex. hip pain) which may confound discrimination of pain assessment in index knee, as judged by the Investigator
- Undergone arthroscopic surgery of the index knee within 6 months of study drug administration, or open surgery to the index knee within 24 months of study drug administration
- Undergone replacement surgery of the index knee
- Presence of surgical hardware or other foreign bodies in the index knee
- Index knee injections with corticosteroids within 30 days, or hyaluronic acid within 3 months, or platelet-rich plasma within 6 months prior to study drug administration.
- Concurrent use of opioids for indications other than knee pain
- Arterial or venous thrombi (including stroke), myocardial infarction, hospital admission for unstable angina, cardiac angioplasty, or stenting within 12 months prior to Screening.
- Sensory peripheral neuropathy in the distal aspect of the target limb that is of moderate severity or higher at Screening
- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or hepatitis C; positive tests for HIV-1 or -2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies
- Specified laboratory abnormalities within 1 week of study drug administration
- History within the past 2 years of substance abuse, including alcohol
- Allergy or hypersensitivity to chili peppers, capsaicin, resiniferatoxin, acetaminophen, tramadol, radiographic contrast agents, or any of the agents to be used for sedation, anesthesia or nerve block on the day of study drug administration
- Female participants who are pregnant, planning on becoming pregnant within 30 days of receiving study drug, or are breastfeeding at Screening
- Any medical condition or medical comorbidities that, in the Investigator's opinion, could adversely impact study participation or safety, conduct of the study, or interfere with pain assessments
- Participated in a clinical study of an investigational drug within 4 half-lives of Screening or are scheduled to receive an investigational agent (therapy or device) while participating in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resiniferatoxin
12.5 ug of Resiniferatoxin in 5 mL volume administered once intra-articularly
|
Resiniferatoxin is a compound purified from natural sources.
Other Names:
|
Placebo Comparator: Placebo
5 mL of diluent in normal saline administered once intra-articularly
|
Diluent in normal saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in WOMAC pain and function subscales combined score
Time Frame: Baseline to Week 12
|
Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 3.1 numerical rating scale (NRS) [0-10 scale] Pain and Function combined score.
The combined score ranges from 0 to 220; a higher score indicates greater severity of disease.
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of RTX: Incidence and severity of adverse events
Time Frame: Baseline through Week 12
|
Incidence and severity of adverse events
|
Baseline through Week 12
|
Change in analgesic usage
Time Frame: Baseline to Week 4, Week 8, Week 12
|
Change in analgesic medication usage as reported by subjects
|
Baseline to Week 4, Week 8, Week 12
|
Change in WOMAC pain and function subscales combined score
Time Frame: Baseline to Week 4, Week 8
|
Change in the WOMAC 3.1 NRS [0-10 scale] Pain and Function combined score.
The combined score ranges from 0 to 220; a higher score indicates greater severity of disease.
|
Baseline to Week 4, Week 8
|
Patient Global Impression of Change (PGIC) in index knee pain
Time Frame: Baseline to Week 4, Week 8, Week 12
|
Rating of change in index knee pain using the 7-point PGIC scale where 1 = very much improved and 7 = very much worsened.
|
Baseline to Week 4, Week 8, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Monica Luchi, MD, Sorrento Therapeutics, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2021
Primary Completion (Anticipated)
June 1, 2022
Study Completion (Anticipated)
June 1, 2022
Study Registration Dates
First Submitted
May 8, 2020
First Submitted That Met QC Criteria
May 12, 2020
First Posted (Actual)
May 13, 2020
Study Record Updates
Last Update Posted (Actual)
November 9, 2021
Last Update Submitted That Met QC Criteria
November 2, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STI-RTX-3004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
Clinical Trials on Resiniferatoxin
-
Sorrento Therapeutics, Inc.CompletedIntractable Cancer PainUnited States
-
Sorrento Therapeutics, Inc.WithdrawnOsteoarthritis, Knee | Knee Pain Chronic
-
National Institute of Neurological Disorders and...Not yet recruitingPeriganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone PainPalliative Care | Intractable PainUnited States
-
Sorrento Therapeutics, Inc.WithdrawnPain, Intractable | Pain Cancer
-
National Institute of Dental and Craniofacial Research...National Institute of Neurological Disorders and Stroke (NINDS); Sorrento Therapeutics...RecruitingPalliative Care | Intractable PainUnited States
-
Sorrento Therapeutics, Inc.SuspendedPain | Pain, Intractable | Pain CancerUnited States
-
Sorrento Therapeutics, Inc.CompletedOsteoarthritis, Knee | Pain, KneeUnited States
-
National Institutes of Health Clinical Center (CC)RecruitingMorton's NeuromaUnited States
-
Sorrento Therapeutics, Inc.Active, not recruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain ChronicUnited States